Targeting of Oncogenic Proteins for Intracellular Degradation

Abstract

Selective depletion of intracellular oncogenic proteins is a potentially powerful tool for the treatment of breast cancer. This is usually achieved by genetic manipulation of the target gene using procedures such as gene disruption, antisense or ribozyme technologies. We now propose an alternative approach in which an oncogenic protein is specifically targeted for intracellular degradation. In order to do this we will take advantage of the permeability properties of the third helix of the antennapedia protein. This will be used to deliver a small trifunctional peptide consisting of a target protein binding peptide and a peptide designed to interact with the E2 class of ubiquitin conjugating enzymes. In this way the ubiquitin-conjugating machinery will be selectively recruited to the target protein which should then be degraded by the proteosome. We will use the cytoplasmic signaling molecule beta-catenin as a model system since its oncogenic activity is thought to be regulated at the level of protein stability and we have established that it is normally targeted for ubiquitination and proteosomal degradation. Mutations of beta-catenin which increase its protein stability are oncogenic. The beta-catenin binding peptide will be based on the region of the tumor suppressor protein APC which constitutively binds beta-catenin.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2001
Accession Number
ADA398341

Entities

People

  • Stephen Byers

Organizations

  • Georgetown University

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Breast Cancer
  • Cells
  • Cultured Cells
  • Degradation
  • Enzymes
  • Genes
  • Genetic Engineering
  • Inhibitors
  • Molecular Weight
  • Molecules
  • Mutations
  • Neoplasms
  • Proteins
  • Suppressors
  • Targeting
  • Targets

Readers

  • Breast cancer cell signaling and growth regulation.
  • Molecular and Cellular Biochemistry

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech